DalsnaFinance

Insulet Corporation $PODD

Health Care · Health Care Equipment · NYSE/NASDAQ

S&P 500 Russell 1000 Massachusetts
Create a scorecard
$142.64
+0.68 (+0.48%)
As of Oct 20, 2026, 8:27 PM EDT
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Aug 6, 2026, the first target we tracked for PODD.

Key facts

52-week range (closes)
$130.47 – $346.36 Lowest close Sep 30, 2026, highest Nov 19, 2025; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Fiscal year ends
December Fiscal 2025 ended Dec 31, 2025, from SEC filings
In the S&P 500 since
Mar 15, 2023, replacing Signature Bank (SBNY) and SVB Financial Group (SIVB) · The FDIC placed Signature Bank into FDIC Receivership. · The FDIC placed SVB's main subsidiary, Silicon Valley Bank, into receivership. · All S&P 500 changes
Analyst coverage
2 open price targets from 2 firms: Jefferies, Raymond James Approved targets tracked here; see the analyst section below

Insulet Corporation (PODD) is trading up at $142.64 (+0.48%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on PODD

Current price targets from 2 firms average $185, ranging from $180 to $190 — 30% above the current $143. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Insulet Corporation revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.71B$1.34B−$28.9MFY2016 revenue: $367.0MFY2016 net income: −$28.9M · Net margin −7.9%'16FY2017 revenue: $463.8MFY2017 net income: −$26.8M · Net margin −5.8%'17FY2018 revenue: $563.8MFY2018 net income: $3.30M · Net margin 0.6%'18FY2019 revenue: $738.2MFY2019 net income: $11.6M · Net margin 1.6%'19FY2020 revenue: $904.4MFY2020 net income: $6.80M · Net margin 0.8%'20FY2021 revenue: $1.10BFY2021 net income: $16.8M · Net margin 1.5%'21FY2022 revenue: $1.31BFY2022 net income: $4.60M · Net margin 0.4%'22FY2023 revenue: $1.70BFY2023 net income: $206.3M · Net margin 12.2%'23FY2024 revenue: $2.07BFY2024 net income: $418.3M · Net margin 20.2%'24FY2025 revenue: $2.71BFY2025 net income: $247.1M · Net margin 9.1%'250%20%40%60%FY2016 net margin: −7.9% (off the scale, which stops at −0.6%)FY2017 net margin: −5.8% (off the scale, which stops at −0.6%)FY2018 net margin: 0.6%FY2019 net margin: 1.6%FY2020 net margin: 0.8%FY2021 net margin: 1.5%FY2022 net margin: 0.4%FY2023 net margin: 12.2%FY2024 net margin: 20.2%FY2025 net margin: 9.1%
Insulet Corporation annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$367.0M$463.8M$563.8M$738.2M$904.4M$1.10B$1.31B$1.70B$2.07B$2.71B
Growth (year over year)+39.1%+26.4%+21.6%+30.9%+22.5%+21.5%+18.8%+30.0%+22.1%+30.7%
Gross profit$211.1M$277.2M$370.2M$480.3M$582.3M$752.1M$805.6M$1.16B$1.45B$1.94B
Gross margin57.5%59.8%65.7%65.1%64.4%68.4%61.7%68.3%69.8%71.6%
Operating income−$10.7M−$7.40M$27.4M$50.0M$51.5M$126.0M$37.6M$220.1M$308.9M$473.8M
Operating margin−2.9%−1.6%4.9%6.8%5.7%11.5%2.9%13.0%14.9%17.5%
Net income−$28.9M−$26.8M$3.30M$11.6M$6.80M$16.8M$4.60M$206.3M$418.3M$247.1M
Net margin−7.9%−5.8%0.6%1.6%0.8%1.5%0.4%12.2%20.2%9.1%
EPS (diluted)−$0.48−$0.46$0.05$0.19$0.10$0.24$0.07$2.94$5.78$3.48
Balance sheet
Cash and equivalents$137.2M$272.6M$113.9M$213.7M$907.2M$806.4M$689.8M$704.2M$953.4M$716.1M
Total assets$456.6M$840.0M$928.7M$1.14B$1.87B$2.05B$2.25B$2.59B$3.09B$3.19B
Total liabilities$393.5M$661.1M$716.6M$1.07B$1.27B$1.49B$1.77B$1.86B$1.88B$1.68B
Long-term debt$332.8M$566.2M$592.0M$887.9M$1.04B$1.25B$1.37B$1.37B$1.30B$930.8M
Shareholders' equity$63.1M$158.5M$212.1M$75.9M$603.6M$556.3M$476.4M$732.7M$1.21B$1.52B
Cash flow
Operating cash flow$15.9M$41.3M$35.9M$98.4M$84.0M−$68.1M$119.0M$145.7M$430.2M$569.3M
Capital expenditure$22.1M$73.8M$157.4M$163.7M$129.0M$111.9M$122.9M$75.6M$124.9M$191.6M
Free cash flow−$6.20M−$32.5M−$121.5M−$65.3M−$45.0M−$180.0M−$3.90M$70.1M$305.3M$377.7M
Share buybacks———————$0$0$59.6M

From Insulet Corporation's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Insulet Corporation vs the Health Care sector and the S&P 500

Insulet Corporation's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Insulet Corporation compared with the median Health Care company and the median S&P 500 company
MeasureInsulet CorporationHealth Care (59 other S&P 500 companies)S&P 500 (502 other companies)
Revenue growth, latest fiscal year+30.7%+7.1%+7.0%
Net margin, latest fiscal year9.1%13.1%13.0%
Share price change, 1 year−56.4%+22.8%+7.5%

Insulet Corporation: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Insulet Corporation included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Insulet Corporation

Headquarters
Acton, Massachusetts From SEC filings, Oct 2026

Recent News (20)

More Health Care stocks

Browse all companies →